AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Groupe Bruxelles Lambert SA

Earnings Release Nov 7, 2024

3955_10-q_2024-11-07_f20fa723-e46d-4c54-8ca3-54762f7db937.pdf

Earnings Release

Open in Viewer

Opens in native device viewer

Ongoing value creation across all asset classes Mid-term objective1 of double-digit TSR per annum driven by NAV per share growth and increasing distributions2 to shareholders off an already enhanced base3

  • Capital gains4 of €1.1bn5 from disposals of listed assets
  • Continued value creation from private assets and GBL Capital reaching + €278m6
  • NAV per share increase to €117.99
  • Liquidity profile of €4.3bn to seize attractive investment opportunities
  • Steady growth in the dividend per share from the increased base of €5.003

Ian Gallienne, CEO of GBL, remarked, "Building on our nine-month results, GBL's teams remain focused on value creation and capital allocation. Over the medium term, our objective is to generate a double-digit total shareholder return annually. We intend to deliver this magnitude of returns through both NAV per share growth and increasing distributions2 to shareholders, while maintaining conservative leverage. As such, we are announcing steady growth in the dividend per share off a significantly increased base of €5.003 . With our solid balance sheet, GBL is well positioned to seize future attractive investment opportunities."

2 Dividends per share

6 Private assets for + €195m (see page 11) and GBL Capital for + €83m (see page 18)

1 Information on GBL's mid-term outlook (2024-2027) can be found in the Strategic Update presentation in the "Investors" section of www.gbl.com

3 Dividend per share of €5.00 payable in FY 2025 for FY 2024 as announced July 31, 2024; as is customary, subject to approval at GBL's General Shareholders' Meeting

4 In accordance with IFRS 9, capital gains (losses) do not impact GBL's consolidated net result

5 Includes capital gains on disposals of (i) €630m in 9M 2024 and (ii) €422m, the latter from forward sales maturing in October 2024

Section I: Overview & Performance

Portfolio

As of September 30, 2024, listed assets accounted for 63% of the portfolio, while private assets and GBL Capital represented 19% and 17%, respectively. The investment to establish Sienna Investment Managers, the core activity of which is third-party asset management (with more than €40bn in AuM at end September 2024), represents €125m, or less than 1% of GBL's NAV.

Highlights 9M 2024

Listed assets: sizeable capital gains1 of €1.1bn2

As part of GBL's strategic shift toward private assets and given the share price rebound of adidas over approximately the past two years, GBL has seized opportunities to crystallize value on its investment. Over the 9M 2024, GBL divested a €999m stake, thereby reducing its holding from 7.6% to 5.1%. These disposals generated a capital gain1 of €630m.

Similarly, GBL executed €653m of forward sales maturing on October 24, 2024, bringing its adidas stake to 3.5% of the capital and generating a capital gain1 of €422m. GBL remains a meaningful shareholder in adidas and reiterates its support to the company, its management and its strategy.

Private assets: ongoing value creation

Consolidated private assets, performance 9M 2024 vs. 9M 2023
Affidea Sanoptis3 Canyon
Sales, €m 757 518 655
Growth, % 20% 24% 6%
Organic growth, % 13%4 11% 6%
EBITDA growth, % 27% 18% - 19%5

Consolidated private assets posted solid double-digit top-line growth, up + 15% on a combined basis.

Source: non-audited company reporting

The healthcare participations reported double-digit organic sales growth, which was significantly complemented by M&A as these companies pursue sector consolidation. Canyon also posted strong sales growth, at + 6%, and once again outpaced the sector. However, profitability5 , and therefore valuation, were impacted. Nevertheless, the consolidated private assets generated an increase in fair value of + €186m6 . The totality of GBL's private assets (including non-consolidated assets or assets accounted for using the equity method) recorded an increase of + €195m7 .

2 Includes capital gains on disposals of (i) €630m in 9M 2024 and (ii) €422m, the latter generated on forward sales maturing in October 2024

7 Affidea, Sanoptis and Canyon (+ €186m in total), Voodoo (+ €10m) and Parques Reunidos (+ €0m)

1 In accordance with IFRS 9, capital gains (losses) do not impact GBL's consolidated net result

3 Includes estimated annualization of closed clinic M&A and clinic M&A projects with signed SPAs at the end of the period, except for organic growth

4 Like-for-like growth, excluding impact of acquisitions done in the latest period and Covid-19 testing

5 EBITDA decline mainly impacted by the reversal of one-off EBITDA adjustments accounted for in 2023 (adjustments for one-off supply chain issues incurred in Q3 2023). Excluding these adjustments, growth would be + 5%

6 Affidea (+ €192m), Sanoptis (+ €54m) and Canyon (- €60m)

GBL Capital: continued solid performance

GBL Capital created + €83m of value across the business, underscoring a solid performance under a new leadership and strategy.

Sienna Investment Managers: dynamic commercial synergies

Sienna Investment Managers generated dynamic commercial synergies, recording net inflows of €1.8bn in Q3 2024, and thereby increasing assets under management to over €40bn.

NAV per share increase

NAV per share of €117.99 represents an increase of + 3.8% compared to the NAV per share at end 20231 .

Dividend per share: strong increase of + 82% to €5.002 proposed for FY 2024

As communicated in GBL's HY 2024 results publication, the group will propose for the FY 2024 a gross dividend per share of €5.002 to be paid in FY 2025. This represents an + 82% increase compared to the previous year and a yield of 7.1%3 . This amount is supported by the strength of GBL's balance sheet and liquidity profile, both of which were reinforced following the value crystallization on disposals within the listed asset portfolio.

Ongoing share buybacks

Given the discount of the share price to NAV (an average of 39.9% in 9M 2024), the group continued to take advantage of attractive market opportunities to buy back shares. Over the period, GBL acquired, directly and through its subsidiaries, 2.8m GBL shares, corresponding to 2.0% of the shares representing the capital as of September 30, 2024, for a total consideration of €190m. These buybacks were realized as part of the group's seventh share buyback envelope (the allocated amount of which is €500m).

Strong financial position to seize attractive opportunities

GBL's liquidity profile was €4.3bn as of September 30, 2024. The group's strong liquidity, low leverage and balanced debt maturity profile position GBL to seize attractive investment opportunities going forward.

Mid-term outlook: double-digit TSR per annum

In parallel with this 9M 2024 results publication, GBL is providing a mid-term Strategic Update. As part of this communication, GBL is announcing its objective to generate double-digit TSR per annum over 2024-2027. This performance will result from: (i) NAV per share growth and (ii) increasing distributions to shareholders through steady growth in the €5.002 dividend per share, while pursuing opportunistic share buybacks and maintaining conservative leverage. Additional information can be found in the "Investors" section of GBL's website.

3 Based on GBL's share price of €69.95 as at September 30, 2024

1 €113.64 based on 146,700,000 shares as of December 31, 2023

2 Payable in FY 2025 for FY 2024; as is customary, subject to approval at GBL's General Shareholders' Meeting

Net asset value

As of September 30, 2024, GBL's net asset value amounts to €16.3bn (€117.99 per share), compared to €16.7bn (€113.64 per share) at year-end 2023. Relative to the share price of €69.95, the discount as of end September 2024 stood at 40.7%.

September 30, 2024 December 31, 2023
% in
capital
Stock
price (€)1
(€m) Variation % in
capital
Stock
price (€)1
(€m)
Listed assets 10,557 - 7% 11,360
SGS 19.13 99.95 3,624 + 28% 19.31 78.34 2,835
Pernod Ricard 6.80 135.60 2,337 - 15% 6.73 159.75 2,749
adidas 5.09 237.90 2,178 - 14% 7.62 184.16 2,526
Imerys 54.72 29.78 1,384 + 5% 54.64 28.48 1,322
Umicore 15.92 11.66 457 - 53% 15.92 24.90 977
Concentrix 13.51 45.78 4092 - 49% 13.17 88.88 8072
Ontex 19.98 8.94 147 + 18% 19.98 7.61 125
TotalEnergies 0.01 58.50 16 - 5% 0.01 61.60 16
GEA 0.06 43.96 5 + 17% 0.06 37.69 4
Private assets 3,263 + 6% 3,067
Affidea 99.04 1,386 + 16% 99.15 1,195
Sanoptis 83.17 883 + 6% 83.36 829
Canyon 48.783 402 - 13% 48.653 460
Voodoo 15.07 297 + 3% 15.90 287
Parques Reunidos 23.00 296 + 0% 23.00 296
GBL Capital 2,845 - 4% 2,951
Sienna Investment Managers4 125 + 14% 110
Portfolio 16,791 - 4% 17,488
Treasury shares 795 - 34% 1,206
Gross debt (3,070) - 14% (3,578)
Concentrix note 4 - 99%5 476
Gross cash 1,810 + 68% 1,080
Net asset value 16,330 - 2% 16,671
Net asset value (€ p.s.)6 117.99 + 4% 113.64
Stock price (€ p.s.) 69.95 - 2% 71.22
Discount 40.7% +339 bps 37.3%

6 Based on 138,400,000 shares as of September 30, 2024 and 146,700,000 shares as of December 31, 2023

1 Share price converted in € based on the ECB fixing of (i) 0.9439 CHF/€ as of September 30, 2024 and 0.9260 CHF/€ as of December 31, 2023 for SGS, (ii) 1.1196 USD/€ as of September 30, 2024 and 1.1050 USD/€ as of December 31, 2023 for Concentrix

2 Including the market value of earn-out shares at September 30, 2024, i.e., €7m, and at December 31, 2023, i.e., €27m

3 GBL's ownership in Canyon, excluding shares held by GBL Capital (additional indirect ownership of 1.34% as of September 30, 2024 and as of December 31, 2023)

4 Valued at the acquisition cost of the management companies less any impairment in value

5 The Concentrix note was monetized in Q3 2024; GBL has a residual receivable of €4m as of September 30, 2024

Net debt and cash flow

Net debt decreased from €2.0bn as of December 31, 2023 to €1.3bn as of September 30, 2024. This decrease mainly reflects divestments and distributions of €1,342m and cash earnings of €315m, partially offset by investments of - €260m (including share buybacks) and the dividend paid by GBL for the year 2023 (- € 380m).

€m Gross cash Gross debt Net debt
Position as of December 31, 2023 1,556.01 (3,577.9) (2,021.9)
Cash earnings 315.2 - 315.211
Dividend FY 2023 (380.5) - (380.5) 1
Investments (260.2) - (260.2)1
GBL (share buybacks) (190.4) - (190.4)1
Sienna Investment Managers (32.4) - (32.4)1
GBL Capital (23.7) - (23.7)1
Other (13.7) - (13.7)1
Divestments/Distributions 1,342.0 - 1,342.01
adidas 999.3 - 999.31
GBL Capital 342.7 - 342.71
Institutional bonds (500.0) 500.0 -
1
Other (258.2)2 7.5 (250.7)2
Position as of September 30, 2024 1,814.3 (3,070.4) (1,256.1)

The LTV3 stood at 7.3%. This compares to 11.4% at the end of December 2023.

Loan To Value

3 Includes gross cash and Concentrix note

1 Includes the Concentrix note, which was monetized in Q3 2024; GBL has a residual receivable of €4m as of September 30, 2024

2 Includes mainly (i) timing differences in some fund distributions received by GBL Capital and upstreamed to GBL (- €149m), (ii) dividends received from GBL Capital presented both in cash earnings and distributions (- €71m) and (iii) the net impact to set up the new group's carried interest scheme (- €27m)

Balance sheet management

€m September 30, 2024 December 31, 2023
Institutional bonds (2,000) (2,500)
Exchangeable bonds into Pernod Ricard shares (500) (500)
Convertible bonds into GBL shares (500) (500)
Other (70) (78)
Gross debt (3,070) (3,578)
Gross cash (excluding treasury shares) 1,810 1,080
Concentrix note 4 476
(Net debt)/Net cash (1,256) (2,022)

The weighted average maturity of the gross debt is 3.9 years at the end of September 2024 (4.0 years at the end of December 2023).

The gross debt does not include the external investment commitments of GBL Capital, which total €831m at the end of September 2024 (€752m at the end of December 2023).

The Concentrix note was estimated at its present value for an amount of €476m at the end of December 2023, and was monetized in Q3 20241 .

As of September 30, 2024, committed credit lines amount to €2,450m, fully undrawn, and mature in 2029.

The liquidity profile (gross cash and undrawn committed credit lines) amounts to €4,260m at the end of September 2024, compared to €3,530m at the end of December 2023.

Finally, as of September 30, 2024, the 11.4m treasury shares correspond to 8.2% of the shares representing the capital on this date and are valued at €795m.

1 GBL has a residual receivable of €4m as of September 30, 2024

Investment category % of
portfolio
Investment Strategy
Listed
assets
2012
START OF THE
PORTFOLIO
REBALANCING
• Leading companies in their sector, with
a clear and sustainable business model
• Majority or minority shareholdings
with influence, enabling a position as a
reference shareholder and an engaged
role in the governance
• Equity investments between
€250m and €2bn
• NAV growth
• Diversification within this
investment category
• Cash flow generation to ensure
the GBL dividend
Private
assets
2019
START OF ACTIVITY
• Leading companies in their sector, with
a clear and sustainable business model
• Mainly majority shareholdings
• Equity investments from
€300m and €1bn
• NAV growth
• Consolidation opportunities
• Attractive returns thanks to
agile structures
• Less replicable portfolio
Indirect
private assets
2013
START OF ACTIVITY
(FORMERLY SIENNA CAPITAL)
• Fund commitments and
co-investments alongside funds
in which GBL is invested
• Private equity funds typically, but also
other strategies (e.g., private credit,
structured equity, secondaries,
value-add infrastructure)
• Exposure to venture capital, growth
equity and hedge funds
• Commitments/investments of
up to €50m, with flexibility to
invest higher amounts in
exceptional circumstances
• NAV growth
• Portfolio diversification
• Downside protection
• Meaningful contributor to
GBL's cash earnings
Asset
management
2021
START OF ACTIVITY
• Platform for third-party asset
management
• Over €40bn under management at the
end of September 2024
• Generation of recurring
revenues
• Regular fundraising across
strategies
• Synergy of expertises gathered
in a single platform
• Benefits from GBL's network

Section II: Details by Investment Category

Listed assets

Listed assets include stakes in SGS, Pernod Ricard, adidas, Imerys, Umicore and Concentrix, among others. As an engaged long-term investor, GBL seeks to invest in high-quality companies that are primarily investment grade and with a leading sector position. GBL contributes to value creation through its involvement in the key governance bodies of its portfolio companies. Listed assets represent 63% of GBL's portfolio at the end of September 2024.

Highlights

  • GBL crystallized value on its adidas shares through €999m of disposals over the 9M 2024. These sales generated a capital gain1 of €630m and reduced GBL's stake from 7.6% to 5.1% of the capital. Furthermore, GBL executed €653m of forward sales maturing on October 24, 2024, bringing its stake to 3.5% of the capital and generating a capital gain1 of €422m. GBL remains a meaningful shareholder in adidas and reiterates its support to the company, its management and its strategy
  • GBL continues to support its portfolio companies. Operational progress continues to be made across the portfolio, with several companies having communicated positive expectations2 for FY 2024 and beyond:
    • o SGS: mid-term objectives include, among other elements, a significant improvement of at least 1.5% in adjusted operating income margin by 2027. In addition, the new CEO, who officially began in Q1 2024, has announced a streamlined Executive Committee to improve efficiency and effectiveness. Over the 9M 2024, SGS generated + 7.8% organic sales growth

2 Please refer to company-specific publications for more detail

1 In accordance with IFRS 9, capital gains (losses) do not impact GBL's consolidated net result

and reiterated its FY 2024 outlook: (i) mid- to high-single-digit organic sales growth, (ii) M&A relaunch, (iii) improvement in adjusted operating income margin on sales, and (iv) strong free cash flow generation

  • o Pernod Ricard: remains confident in its mid-term financial framework, aiming for the upper end of + 4% to + 7% organic net sales growth and + 50 to + 60 bps organic operating margin improvement despite a slow start to its Q1 FY 2025
  • o adidas: raised its FY 2024 guidance upon better-than-expected Q3 2024 results. adidas now expects FY 2024 currency-neutral sales to grow approximately + 10%, compared to prior guidance of a high-single-digit increase. Moreover, operating profit is expected to reach approximately €1.2bn, compared to prior guidance of €1.0bn

Listed assets – NAV evolution

The NAV of the listed assets as of September 30, 2024 stood at €10.6bn, compared to €11.4bn as of December 31, 2023. The evolution is partly attributable to a reduction in the group's stake in adidas, representing €999m, as GBL crystallized value on its investment. The increase in fair value amounted to + €184m, with significant contributions from SGS and adidas, thanks to strong double-digit share price increases. These positive share price evolutions compensated softer performances of Umicore, Pernod Ricard and Concentrix.

Listed assets – NAV evolution
€m 9M 2024 Q3 2024
NAV, beginning of period 11,360 10,033
Acquisitions 13 -
Disposals (999) -
Change in fair value 184 525
NAV, end of period 10,557 10,557
Listed assets – contribution to NAV
9M 2024 Q3 2024
€m NAV Change in fair
value
Change in fair
value
SGS 3,624 783 613
Pernod Ricard 2,337 (415) 153
adidas 2,178 652 136
Imerys 1,384 60 (177)
Umicore 457 (519) (93)
Concentrix (ordinary + earn-out shares) 409 (398) (122)
Ontex 147 22 14
TotalEnergies 16 (1) (1)
GEA 5 1 1
Total 10,557 184 525

Private assets

Private assets include controlling stakes in Affidea, Sanoptis and Canyon (consolidated assets) as well as minority stakes in Voodoo and Parques Reunidos (non-consolidated assets or assets accounted for using the equity method). Given the attractive long-term potential of private assets, GBL has increased over time its involvement in this asset category, which represents 19% of the portfolio as of the end of September 2024.

Highlights

  • Private assets contributed to + €195m1 in value creation
  • Consolidated private assets reported strong double-digit sales growth of + 15%, on a combined basis

1 Affidea (+ €192m), Sanoptis (+ €54m), Canyon (- €60m), Voodoo (+ €10m) and Parques Reunidos (+ €0m)

Private assets – NAV evolution

At the end of September 2024, the NAV stood at €3.3bn, an increase of + €196m compared to year-end 2023. This increase reflects, in particular, the uplift in fair value of healthcare platforms Affidea and Sanoptis at + €192m and + €54m, respectively.

Private assets – NAV evolution
€m 9M 2024 Q3 2024
NAV, beginning of period 3,067 3,191
Acquisitions 1 -
Disposals - -
Change in fair value 195 72
Affidea 192 89
Sanoptis 54 12
Canyon (60) (32)
Voodoo 10 3
Parques Reunidos 0 0
NAV, end of period 3,263 3,263
consolidated assets 2,671 2,671
non-consolidated assets
or assets accounted for using the equity method
593 593

Consolidated private assets – valuation

Over the 9M 2024, the healthcare platforms reported an increase in NAV, driven by robust business development both organically and from M&A. From an operational perspective, Canyon continues to outperform its peers. However, the challenging market environment in 2024 has slightly impacted the 2025 outlook, and therefore valuation.

Consolidated private assets – valuation1
€m Acquisition
year
MoIC NAV
9/30/2024
NAV
6/30/2023
Variation
(3 months)
NAV
12/31/2023
Variation
(9 months)
Major Drivers
Affidea 2022 1.4x 1,386 1,298 + 89 1,195 + 192 Continued strong
growth, both organic
and from M&A,
including the
MedEuropa acquisition
(closed in May 2024);
Solid cash flow
generation
Sanoptis 2022 1.3x 883 871 + 12 829 + 54 High growth, from
organic initiatives and
M&A, combined with
significantly expanded
platform capabilities
(e.g., successful entry
into 4 new
geographies,
substantial
reinforcement of
shared functions and
investments into new
technologies)
Canyon 2021 1.1x 402 434 - 32 460 - 60 Continued challenging
market environment
(i.e., oversupply
leading to high
discounts on certain
bike categories),
impacting 2024 and
resulting in a slight
downward revision of
the 2025 financial
outlook

1 The private assets are valued quarterly at their fair value, using a multi-criteria approach (e.g., DCF, multiples, trading comps), in line with IPEV Valuation Guidelines. Acquisitions are held at cost for 12 months, provided this is the best estimate of fair value

The pan-European provider of advanced diagnostics and outpatient services

Acquired in 2022

Highlights

€1,386m NAV as of 9/30/2024 + €192m compared to 12/31/2023

dlhgjh

  • Sales grew + 20% (+ 13% organically1), driven by continued solid commercial momentum and clinic acquisitions. All countries and channels (outpatient services, diagnostic imaging, lab testing and cancer care) contributed to growth +m
  • EBITDA grew + 27%, outpacing sales, thanks to operating leverage and margin initiatives, with further upside likely as greenfield-brownfield projects ramp up and acquisitions are integrated
  • The number of locations increased by +46 to 380, driven by acquisitions and greenfields. Affidea completed 24.2m examinations vs. 22.8m in 9M 2023
  • Other 9M 2024 highlights included:
    • o Completion of 12 acquisitions, including two renowned cancer care providers, MedEuropa in Romania (May 2024) and Nu-Med in Poland (August 2024), as well as two leading clinics in Switzerland (March 2024)
    • o Successful raising of two incremental Term Loan B facilities of (i) €200m (February 2024) and (ii) €125m (July 2024), as well as the repricing of the existing facility, providing further runway to pursue value-accretive investments and M&A
    • o Further reinforcement of the Supervisory Board with Frans van Houten (former CEO of Philips) who joined as a Non-Executive Director
    • o Continued roll-out across clinics of AI solutions focused on (i) facilitating scan interpretation and (ii) managing the patient pathway (e.g., assistance with bookings or follow-up scans). These initiatives will result in better patient outcomes, while improving productivity
Key metrics, Affidea
Evolution since 9M 9M GBL entry -
GBL's entry 20242 20232 LTM ending
June 30, 2022
Sales3
, €m
+ 284 757 632 698
Growth, % + 41% + 20% + 19% -
Organic growth1
, %
+ 30% + 13% + 16% -
EBITDA growth4
, %
+ 57% + 27% + 22% -
Number of locations5 + 65 380 334 315
Number of examinations, millions + 19% 24.2 22.8 26.8

Source: Non-audited internal reporting

3 Reported sales

5 Pro forma for acquisitions

1 Like-for-like growth, excluding impact of acquisitions done in the latest period and Covid-19 testing

2 Growth metrics vs. same period of previous year (at constant currency within the year)

4 Pro forma for the full latest period of acquisitions done in that period, excluding Covid-19 testing and equipment lease

A European leader in ophthalmology services

Acquired in 2022

Highlights

  • Sales grew + 24% (+ 11% organically) and EBITDA + 18%. Organic sales growth is supported by further investments in state-of-the-art equipment and people, leading to material productivity increases +m
  • Sanoptis acquired 11 surgical centers in 9M 2024 and is now present in 447 locations (+ 168 since GBL's entry) with 835 doctors (+ 320 since GBL's entry)
  • The company performed 3.3m core surgical and conservative treatments over LTM ending September 30, 2024, + 1.4m (+ 75%) compared to LTM volumes at GBL's entry, driven by higher volume at existing locations and M&A
  • Sanoptis successfully continues its internationalization strategy (i.e., beyond Switzerland and Germany), having entered the Spanish market in 2024. The group's international footprint consists of the following clinical centers:
    • o 2 in Spain (Badajoz and Bilbao)
    • o 4 in Italy (Udine, Milano, Florence and Saronno)
    • o 3 in Austria (Salzburg, Innsbruck and Vienna)
    • o 2 in Greece (Athens and Thessaloniki)
  • Sanoptis further solidified its position as the leader in innovation, having led in October 2024 a Series B funding round in Ikerian, a company leveraging AI in ophthalmic diagnostics. As part of this investment, Sanoptis entered into a commercial agreement to expand across Europe Ikerian's AI-powered RetinAI Discovery platform
  • To support future growth, particularly in international markets, the company further reinforced its shared functions including in the Operations, Business Development, Finance and People/HR teams
Key metrics1
, Sanoptis
Evolution 9M 9M GBL entry -
since
GBL's entry
20242 20232 LTM ending
June 30, 2022
Sales, €m + 322 518 419 350
Growth, % 95% 24% 42%3 -
Organic growth4
, %
20% 11% 11%3 -
EBITDA growth, % 95% 18% 46%3 -
Number of locations + 168 447 386 279
Number of doctors + 320 835 686 515
Number of treatments5
, 000s
+ 1,415 2,404 2,200 1,876

Source: Non-audited internal reporting

5 Core surgical and conservative (e.g., diagnostic) treatments

1 All periods include annualization of closed clinic M&A and clinic M&A projects with signed SPAs at the end of the period except for organic growth

2 Growth metrics vs. same period of last year

3 Restated reflecting updated signing date of pipeline M&A

4 Organic growth uses the perimeter of the earliest period annualized for closed clinic M&A

World's largest Direct-to-Consumer manufacturer of premium bikes

Acquired in 2021

Highlights

€402m NAV as of 9/30/2024 - €60m compared to 12/31/2023

dlhgjh

  • Sales grew + 6%, despite a market environment that remained challenging due to market oversupply in certain categories and deep discounts, particularly on electric and non-electric mountain and urban bikes +m
  • Demonstrating the strength of the brand, Canyon continued to gain market share, primarily in the segments premium road and gravel, but group profitability was affected
  • Canyon maintained focus on innovation and product excellence, as evidenced by multiple awards in Q3, including:
    • o "Road Bike of the Year" from Tour Magazin for the Endurace CFR
    • o 1 st place in the Top Vélo Awards 2024 from Top Vélo magazine for the Aeroad CFR
  • Canyon's athletes continued to deliver landmark victories, including:
    • o Women's Tour de France (Kasia Niewiadoma)
    • o Gravel World Championship gold medal and Road World Championship bronze medal (Mathieu van der Poel)
  • In July 2024, the company launched the "Find Your Freedom" marketing campaign in collaboration with NBA superstar LeBron James, a brand ambassador and Canyon investor since July 2022. This campaign takes the relationship between Canyon and LeBron James to the next level, thereby significantly expanding Canyon's reach
Key metrics1
, Canyon
Evolution since 9M 9M GBL entry -
GBL's entry 20242 20232 FY 2020
Sales, €m + 417 655 621 408
Growth, % + 102% 6% 23% -
Organic growth, % + 102% 6% 23% -
EBITDA growth3
, %
+ 3% (19)%4 (6)%5 -
Number of employees + 665 1,655 1,695 990

Source: Non-audited internal reporting

5 Impacted by: (i) higher discounts on certain categories and (ii) a strong comparable period which benefited from the sale of high-margin models

1 At yearly average FX rates; local GAAP, pre IFRS

2 Growth metrics vs. same period of the previous year

3 Adjusted EBITDA

4 EBITDA decline mainly impacted by the reversal of one-off EBITDA adjustments accounted for in 2023 (adjustments for one-off supply chain issues incurred in Q3 2023). Excluding these adjustments, growth would be + 5%

One of the world's leading mobile game publishers by downloads

Minority stake taken in 2021

Highlights

NAV as of 9/30/2024 + €10m compared to 12/31/2023

  • Sales growth was driven mainly by the hybrid casual gaming segment, with hits such as Mob Control, Block Jam 3D and Collect Em All +m
  • Profitability improved due to operating leverage and strict cost discipline, particularly in user acquisition expenses
  • Voodoo is continuing its diversification strategy, pivoting towards higher-value gaming segments and apps
  • Aligned with this strategy, Voodoo announced in June 2024 the acquisition of BeReal, a leading social media platform
    • o This transaction significantly expands Voodoo's footprint in social media, adding a loyal global user base of over 40m monthly active users, and provides opportunities for synergies in product development, monetization and costs
Key metrics, Voodoo
9M 9M
20241 20231
Sales, €m 430 390
Growth, % 10% 14%2

2 Adjusted for a one-off effect in 9M 2022, when Voodoo enjoyed a revenue inflow related to a deal with a leading ad mediation platform

1 Growth metric vs. same period of previous year

A leading operator of leisure parks with a global presence

Minority stake since 2017 (company taken private in 2019)

+m

Highlights

  • Sales growth of + 2% (organic) was primarily driven by a greater number of visitors, in a context of resilient spend per capita
  • Growth came from most key countries and park types (theme, animal and water)
  • Solid performance over the summer, despite a weaker macroeconomic outlook in the US softening consumer spending
Key metrics, Parques Reunidos
9M 9M
2024
1
2023
1
Sales, €m 714 699
Growth, % 2% 3%

1 Growth metric vs. same period of previous year

Indirect private assets

GBL Capital, established in 2013, is the group's indirect private asset activity that invests in funds and co-investments. The NAV of this activity represents 17% of GBL's portfolio as of the end of September 2024.

NAV evolution

GBL Capital's NAV stood at €2.8bn at the end of September 2024. Funds represented 50% of total assets, co-investments 35% and Sienna branded funds and co-investments 9%. GBL Capital's value creation amounted to + €83m over the period, but due to high distributions (€343m), NAV decreased.

Distributions mainly came from funds Apheon (€201m), Sagard (€64m), Kartesia (€47m) and BDT (€16m) while the most significant contributions to value creation came from growth at Apheon (+ €48m) and Sagard (+ €21m).

The most significant investments were capital calls for ICONIQ (€32m) and in Sienna Private Credit (€29m). Moreover, in July 2024, GBL Capital concluded a secondary transaction with a leading institutional investor involving the disposal of a portion of certain fund interests, mainly managed by Sagard, for total proceeds of €102m. This disposal generated a capital gain of €13m. This institutional investor has committed to invest €40m to Sienna Private Equity Fund I.

GBL Capital – NAV evolution
€m NAV
9/30/2024
Value
creation
Distributions Investments Other NAV
12/31/2023
Funds 1,432 74 (338) 51 - 1,644
Co-investments 1,002 3 (1) (9) - 1,009
Sienna branded funds and co-investments 263 5 (3) (36) - 297
Other (GBL Capital cash and working capital) 149 - - 19 130 -
Total 2,845 83 (343) 24 130 2,951
GBL Capital, NAV
€m 12/31/2023 Investments Distributions Value Creation Other 9/30/2024
Apheon 401.9 4.2 (201.4) 47.8 - 252.5
Sagard 326.6 (46.8) (63.8) 21.5 - 237.5
Human Capital 174.6 8.6 - (1.8) - 181.4
Backed 154.5 8.4 (3.7) (4.4) - 154.9
BDT 133.6 0.6 (16.3) 1.3 - 119.2
Marcho Partners 96.5 - (0.1) 3.8 - 100.2
Kartesia 133.0 - (47.4) 4.8 - 90.4
C2 Capital 75.0 1.7 - (3.0) - 73.7
ICONIQ 15.8 32.3 - (1.2) - 46.9
Stripes 29.8 3.1 - (2.8) - 30.1
468 Capital 18.0 6.7 - (1.2) - 23.6
CIEP II 19.0 0.6 - 1.4 - 20.9
Griffin 16.5 1.6 (0.3) (0.1) - 17.7
Mérieux 18.1 0.5 (1.3) (1.0) - 16.3
PrimeStone 15.9 - (0.3) 0.6 - 16.2
Alto Capital V 1.2 13.3 - (0.2) - 14.4
Epiris - 5.6 (0.1) 7.5 - 13.0
Innovius 6.6 2.5 - 0.0 - 9.1
SPC 7.6 1.0 - 0.2 - 8.8
Dover - 3.7 (0.3) 0.9 - 4.3
Warburg - 3.0 (3.0) 1.4 - 1.5
Bregal - - - (1.1) - (1.1)
Funds 1,644.3 50.8 (338.0) 74.5 - 1,431.6
Upfield 424.6 - - (0.0) - 424.6
Cepsa 95.4 0.3 - 7.4 - 103.2
opseo 65.9 - - 3.3 - 69.1
proALPHA 59.5 - - 6.3 - 65.8
svt
Ceva
52.5
40.4
-
-
-
-
3.2
3.5
-
-
55.7
43.9
Commure 39.8 - - (0.5) - 39.3
Wella 32.2 - - 2.2 - 34.4
Elsan 37.5 - - (5.0) - 32.4
Ginger 30.8 (4.9) (1.0) 2.3 - 27.2
ADIT 28.1 (4.9) (0.4) 4.2 - 27.0
Illumio 24.3 - - (0.3) - 24.0
Transcarent 17.7 - - (0.2) - 17.4
Canyon 13.0 - - (1.6) - 11.4
Globality 10.0 - - - - 10.0
Telenco 9.4 - - (0.5) - 8.9
Sagard NewGen Pharma 5.0 - - (0.0) - 5.0
Klarna 2.6 - - - - 2.6
Cosmetics company 20.8 - - (20.8) - -
Co-investments 1,009.4 (9.5) (1.4) 3.4 - 1,002.0
Sienna Private Equity 150.4 (41.7) (1.8) 4.2 - 111.2
Sienna Private Credit 74.3 29.2 (1.5) 2.9 - 104.9
Sienna Venture Capital 32.1 6.2 - (2.2) - 36.1
Sienna Private Assets
Allocation - 10.0 - 0.5 - 10.5
Sienna Opportunities funds 40.2 (40.1) - (0.1) - -
Sienna branded funds and 297.1 (36.4) (3.3) 5.3 - 262.6
co-investments
Other (GBL Capital cash and - 18.8 - - 130.3 149.0
working capital)
Total GBL Capital 2,950.8 23.7 (342.7) 83.1 130.3 2,845.2

Asset management

Sienna Investment Managers ("Sienna IM") is a multi-expertise pan-European asset manager, building innovative investment strategies spanning listed and private assets, with a long-term perspective and a strong ESG focus. Sienna IM's third-party assets under management total over €40bn as of the end of September 2024.

Highlights

  • Ongoing business development, with €1.8bn of net inflows in Q3 2024
  • Listed assets: a new €2bn mandate for AGIRC-ARRCO, the French supplementary employee pension fund, as part of Sienna IM's partnership with Malakoff Humanis
  • Start of investments in the new FCPR1 Sienna Private Assets Allocation fund
  • Real Estate: closing of inaugural deals in new countries (Ireland, Great Britain and Poland)
  • Sienna IM's branch in Italy, Ver Capital, closed its Special Situations fund and was recognized as the Lender of the Year - Senior Private Debt by financecommunity.it

Performance

Sienna Investment Managers – Net economic result
9/30/2024
€m Net economic result
Revenues 892
Operating expenses (88)
EBITDA 1
Financial results (1)
Other (26)
Net economic result (25)

2 Includes €9m of fees from GBL Capital

1 Fonds communs de placement à risque = high-yield mutual funds

Section III: Key Financial Data1

€m End of September End of December
(Group's share) 2024 2023 2023 Variation2
Consolidated net result 55 1,726 1,723 (1,671)
Consolidated net result per share3 0.41 12.22 12.28 (11.80)
Cash earnings 315 371 414 -15.0%
Cash earnings per share3 2.28 2.53 2.82 -9.9%
Net asset value 16,330 16,018 16,671 -2.0%
Net asset value per share3 117.99 109.19 113.64 +3.8%
Market capitalization 9,681 10,351 10,448 -7.3%
Market capitalization per share3 69.95 70.56 71.22 -1.8%
Discount 40.7% 35.4% 37.3% +3.4%
Net investments /
(divestments)
(1,082) (506) (595) (576)
Net cash / (Net debt) (1,256) (2,164) (2,022) 766
Loan To Value 7.3% 12.4% 11.4% -4.0%

3 Calculation per share based on the number of shares issued as of September 30, 2024, December 31, 2023 and September 30, 2023 (138.4m, 146.7m and 146.7m respectively), except for the net result per share which refers, in accordance with IFRS, to the weighted average number of shares (133.2m, 140.3m and 141.3m respectively) used to determine the basic earnings per share

1 The definitions of alternative performance indicators and, where applicable, their calculation methods can be found in the glossary available on GBL's website: www.gbl.com/en/glossary

2 Variation between September 2024 and September 2023 for the consolidated net result, cash earnings and net investments/(divestments), and between September 2024 and December 2023 for net asset value, market capitalization, discount, net debt and Loan To Value

Consolidated results (economic presentation1 )

€m September 30, 2024 September 30,
Group's share 2023
Cash
earnings
Mark to
market
and other
non-cash
items
Operating
companies
(associated or
consolidated)
GBL
Capital
Sienna
Investment
Managers
Eliminations,
capital gains,
impairments
and reversals
Consolidated Consolidated
Profit (loss) of associates and
consolidated operating
companies
- - (141.5) 31.4 (12.1) - (122.2) 65.0
Net dividends from
investments
345.8 2.3 - - - (134.1) 214.1 238.2
Interest income (expenses) (1.5) (3.9) - (5.6) (0.4) - (11.5) (31.3)
Other financial income
(expenses)
10.0 (1.2) - 70.1 - (25.5) 53.5 354.2
Other operating income
(expenses)
(40.6) (25.8) - (41.3) (12.5) - (120.2) (193.7)
Gains (losses) from
disposals, impairments and
reversal of non-current
assets
1.6 - - 40.5 (0.4) 0.1 42.0 1,294.4
Taxes (0.2) - - (0.4) - - (0.5) (0.3)
IFRS consolidated net
result 2024 (Group's share)
(9 months)
315.2 (28.6) (141.5) 94.8 (25.4) (159.4) 55.1
IFRS consolidated net result
2023 (Group's share)
(9 months)
371.0 103.1 1,337.1 131.0 (14.6) (201.1) 1,726.5

Cash earnings (€315m compared to €371m)

€m September 30, 2024 September 30, 2023
Net dividends from investments 345.8 416.9
Interest income (expenses) (1.5) (29.0)
GBL Capital interests 9.5 1.1
Other interest income (expenses) (11.0) (30.1)
Other financial income (expenses) 10.0 20.5
Other operating income (expenses) (40.6) (37.4)
Gains (losses) from disposals, impairments and
reversal of non-current assets
1.6 -
Taxes (0.2) (0.1)
Total 315.2 371.0

Net dividends from investments received as of September 30, 2024 (€346m) decreased in comparison with September 30, 2023, mainly following the exceptional dividend paid by Imerys in 2023 in addition to its ordinary dividend and linked to the disposal of the HTS business line (impact of - €109m) and the absence of contribution from Holcim as a consequence of the exit from the residual position during 2023 (impact of - € 34m), partially compensated by a contribution from GBL Capital in 2024 (impact of €71m).

1 The definitions of alternative performance indicators and, where applicable, their calculation methods can be found in the glossary available on GBL's website: www.gbl.com/en/glossary

€m September 30, 2024 September 30, 2023
SGS 125.6 117,7
GBL Capital 71.5 -
Imerys 62.6 178.6
Pernod Ricard 40.5 35.4
Umicore 31.4 31.4
Concentrix 7.0 -
adidas 6.3 8.2
TotalEnergies 0.7 0.6
GEA 0.1 9.9
Holcim - 33.6
Mowi - 1.4
Other 0.1 0.1
Total 345.8 416.9

Interest income (expenses) (- €1m) mainly comprise (i) income from gross cash (€22m compared to €12m as of September 30, 2023), (ii) interest from the Concentrix note (€16m compared to €0m as of September 30, 2023), (iii) interest income from GBL Capital (€10m compared to €1m as of September 30, 2023) partially balanced by (iv) interest expenses related to the institutional bonds and the Pernod Ricard exchangeable bond (- €46m compared to - €41m as of September 30,2023).

Other financial income (expenses) (€10m) mainly comprise (i) the dividend received on treasury shares for €25m (€22m as of September 30, 2023) and (ii) yield enhancement income of €4m (€5m as of September 30, 2023), partially balanced by (iii) fees on financial transactions (- €13m).

Gains (losses) from disposals, impairments and reversal of non-current assets (€2m) is composed of the accounting result1 on the partial disposal of the Concentrix note.

Mark to market and other non-cash items (- €29m compared to €103m)

€m September 30, 2024 September 30, 2023
Net dividends from investments 2.3 (0.1)
Interest income (expenses) (3.9) (4.9)
Other financial income (expenses) (1.2) 103.3
Other operating income (expenses) (25.8) 4.8
Total (28.6) 103.1

Other operating income (expenses) notably include the impact of the new group's carried interest scheme implemented in January 2024 (- €27m).

1 Excluding bank fees

Operating companies (associates or consolidated) (- €142m compared to €1,337m)

In accordance with accounting principles, GBL includes in its accounts its share of the net results of the participations in which it holds the majority of the capital or on which it has a significant influence.

€m September 30, 2024 September 30, 2023
Profit (loss) of associates and consolidated operating
companies
(141.5) 51.1
Other financial income (expenses) - 106.5
Other operating income (expenses) - (112.3)
Gains (losses) on disposals, impairments and reversals
of non-current assets
- 1,291.8
Total (141.5) 1,337.1

Profit (loss) of associates and consolidated operating companies amounts to - €142m compared to €51m as of September 30, 2023.

€m September 30, 2024 September 30, 2023
Imerys (78.8) 100.9
Sanoptis (39.2) (31.5)
Affidea (16.3) (33.2)
Parques Reunidos/Piolin II (7.0) 0.6
Canyon (0.2) (0.2)
Webhelp - 14.4
Total (141.5) 51.1

Imerys (- €79m compared to €101m)

Net current income from continued activities, group's share, increases 11.4% to €214m as of September 30, 2024 (€192m as of September 30, 2023). The adjusted EBITDA amounts to €532m (€517m as of September 30, 2023). The net result, group's share, amounts to - €143m as of September 30, 2024 (€184m as of September 30, 2023).

The net result, group's share as of September 30, 2024 is impacted by the recycling in the income statement of translation adjustments relating to assets serving the paper market (mainly arising from the devaluation of the Brazilian real) following their disposal. Imerys shareholders' equity and cash position are not affected by this €302m loss.

Imerys contributes - €79m to GBL's result as of September 30, 2024 (€101m as of September 30, 2023), reflecting the variation in net income, group's share, and the 54.98% consolidation rate for Imerys (54.91% as of September 30, 2023).

The press release relating to Imerys' results as of September 30, 2024 is available at www.imerys.com.

Sanoptis (- €39m compared to - € 31m)

As of September 30, 2024, Sanoptis' contribution to GBL's result amounts to - €39m (- €31m as of September 30, 2023), based on a net result of - €48m (- €40m as of September 30, 2023) and taking into account an integration rate of 83.11% (83.16% as of September 30, 2023).

Affidea (- €16m compared to - €33m)

As of September 30, 2024, Affidea's contribution to GBL's result amounts to - €16m (- €33m as of September 30, 2023), based on a net result of - €17m (- €40m as of September 30, 2023) and taking into account an integration rate of 98.98% (99.00% as of September 30, 2023).

Parques Reunidos/Piolin II (- €7m compared to €1m)

As of September 30, 2024, the contribution amounts to - €7m (€1m as of September 30, 2023), considering a net result of Piolin II of - €30m (€3m as of September 30, 2023) and taking into account an integration rate of 23.10% (23.10% as of September 30, 2023).

Canyon (- €0m compared to - €0m)

As of September 30, 2024, Canyon's contribution to GBL's result amounts to - €0m (- €0m as of September 30, 2023), based on a net result of €0m (- €2m as of September 30, 2023) and taking into account an integration rate of 48.78% (47.96% as of September 30, 2023).

Webhelp

As of September 30, 2023, Webhelp's contribution to GBL's result amounted to €14m.

In addition, the other financial income (expenses) and other operating income (expenses) reflected the change in debts to Webhelp's minority shareholders.

At the closing of the sale of Webhelp as of September 25, 2023, the debt on minority shareholders was extinguished, without any impact on GBL's cash.

GBL Capital (€95m compared to €131m)

€m September 30, 2024 September 30, 2023
Profit (loss) of associates and consolidated operating
companies
31.4 20.6
Interest income (expenses) (5.6) 2.5
Other financial income (expenses) 70.1 146.3
IFRS 9 66.5 125.9
Other 3.7 20.5
Other operating income (expenses) (41.3) (40.9)
Gains (losses) on disposals, impairments and reversals
of non-current assets
40.5 2.5
Taxes (0.4) (0.1)
Total 94.8 131.0

The contribution to GBL's results as of September 30, 2024 of GBL Capital's investments consolidated or accounted for by the equity method amounts to €31m, compared to €21m a year earlier:

€m September 30, 2024 September 30, 2023
AMB IV 35.7 34.2
Operating subsidiaries of AMB III 0.6 (6.4)
Landlife Holding - (0.0)
AMB I & II (0.0) (0.0)
Canyon (0.0) (0.0)
Mérieux Participations 2 (0.5) (10.0)
Backed 1, Backed 2 and Backed Encore 1 (4.4) 2.8
Total 31.4 20.6

Interest income (expenses) (- €6m) include notably interest charges to GBL (- €10m compared to - €1m as of September 30, 2023).

Other financial income (expenses) mainly reflect the change in fair value of the investments not consolidated or not accounted for by the equity method, in application of IFRS 9, for a total amount of €66m (€126m as of September 30, 2023), out of which mainly Sagard funds I - 4 (€25m), Epiris (€10m), Cepsa (€8m) and a cosmetics company (- €21m). As of September 30, 2023, this section included mainly Upfield (€25m), Sagard funds I - 4 (€20m), Marcho Partners (€16m), Kartesia funds (€15m), BDT (€11m) and Cepsa (- €11m).

The gains (losses) on disposals, impairments and reversals of non-current assets mainly include, as of September 30, 2024, the net capital gain following the sale of Beltaste-Vanreusel and Visionnaire by AMB III (€41m).

Sienna Investment Managers (- €25m compared to - €15m)

€ m September 30, 2024 September 30, 2023
Profit (loss) of associates and consolidated operating
companies
(12.1) (6.6)
Interest income (expenses) (0.4) -
Other operating income (expenses) (12.5) (8.0)
Gains (losses) on disposals, impairments and reversals
of non-current assets
(0.4) (0.0)
Total (25.4) (14.6)

The contribution to GBL's results as of September 30, 2024 of Sienna Investment Managers' investments consolidated or accounted for by the equity method amounts to - €12m, compared to - €7m a year earlier:

€m September 30, 2024 September 30, 2023
Sienna Gestion (11.1) (0.3)
Sienna Real Estate (1.2) (5.4)
Sienna Private Credit 0.1 (0.9)
Total (12.1) (6.6)

Eliminations, capital gains, impairments and reversals (- €159m compared to - €201m)

€m September 30, 2024 September 30, 2023
Net dividends from investments (134.1) (178.6)
Other financial income (expenses) (25.5) (22.5)
Gains (losses) from disposals, impairments and reversal
of non-current assets
0.1 -
Total (159.4) (201.1)

Net dividends from investments (associates or consolidated companies) are eliminated and are related in 2024 to GBL Capital (- €71m) and Imerys (- €63m compared to - €179m as of September 30, 2023).

The other financial income (expenses) include mainly the elimination of the dividend on treasury shares amounting to - €25m (- €22m as of September 30, 2023).

Consolidated results (IFRS presentation)

The following table presents GBL's IFRS income statement broken down into six segments:

  • Holding: consisting of the parent company GBL and its subsidiaries. Its main activity is to manage investments as well as the non-consolidated operating companies and associates;
  • Imerys: consisting of the Imerys group, a French group listed on Euronext Paris and holding leading positions in each of its three main business lines: Performance Minerals, Refractory, Abrasives & Construction and Solutions for the Energy Transition;
  • Canyon: consisting of the Canyon group, a non-listed German group, the world leader in exclusively online direct-to-consumer ("DTC") sales of premium bicycles, as well as the dedicated investment vehicle, GfG Capital Sàrl;
  • Affidea: comprising the non-listed Affidea group, leading European provider of advanced diagnostics and outpatient services, and the dedicated investment vehicles to Celeste Capital Sàrl;
  • Sanoptis: comprising the non-listed Sanoptis group, a European leader in ophthalmology services including surgeries and diagnostics, and the dedicated investment vehicles to Sofia Capital Sàrl; and
  • GBL Capital and Sienna Investment Managers ("SIM"): including
    • GBL Capital, with its investment's activity, which includes investments in alternative funds and direct co-investments in private equity, as well as, under consolidated operating activities, the operating subsidiaries of Apheon MidCap Buyout III ("AMB III") (subgroups Vanreusel, etc.)
    • Sienna Investment Managers, a third-party asset management activity, through its stake in Sienna Real Estate, Sienna Gestion and Sienna Private Credit.

The results of a segment include all the items directly attributable to it.

Capital/SIM
Sanoptis
Holding
Canyon
Affidea
Consolidated
Consolidated
Imerys
GBL
Share of profit (loss) of associates
(7.0)
-
-
-
-
30.8
23.8
27.6
Net dividends from investments
214.1
-
-
-
-
-
214.1
238.2
Other operating income (expenses) from
(66.4)
-
(0.4)
(0.2)
(0.2)
(64.8)
(132.0)
(83.7)
investing activities
Gains (losses) from disposals,
impairments and reversals of non
1.8
-
-
-
-
45.0
46.7
3.1
current assets from investing activities
Financial income (expenses) from
(22.1)
-
-
(0.0)
-
73.6
51.6
215.0
investing activities
Profit (loss) before taxes from investing
120.4
-
(0.4)
(0.2)
(0.2)
84.6
204.1
400.2
activities - continuing operations
Turnover
-
2,773.2
653.7
749.3
488.3
77.7
4,742.2
4,651.0
-
Raw materials and consumables
-
(909.7)
(414.9)
(84.1)
(93.8)
(0.0)
(1,502.5)
(1,588.1)
-
Employee expenses
-
(675.1)
(79.6)
(383.9)
(201.2)
(32.0)
(1,371.8)
(1,251.9)
-
Depreciation on tangible and intangible
-
(211.6)
(33.7)
(99.9)
(44.0)
(6.3)
(395.4)
(384.1)
-
assets
Other operating income (expenses) from
-
(672.6)
(110.1)
(130.2)
(85.6)
(36.1)
(1,034.6)
(1,027.5)
-
operating activities
Gains (losses) from disposals,
impairments and reversals of non
-
(334.7)
-
0.6
-
0.9
(333.1)
(61.9)
-
current assets from operating activities
Financial income (expenses) from
-
(39.2)
(13.1)
(56.6)
(99.7)
(5.5)
(214.0)
(195.0)
-
operating activities
Profit (loss) before taxes from
consolidated operating activities -
-
(69.6)
2.3
(4.8)
(35.9)
(1.2)
(109.3)
142.6
continuing operations
-
Income taxes
(0.2)
(71.1)
(2.0)
(11.1)
(11.2)
(0.9)
(96.5)
(85.5)
-
Profit (loss) from continuing operations
120.2
(140.7)
(0.1)
(16.2)
(47.3)
82.4
(1.7)
457.3
-
Profit (loss) from consolidated
operating activities - discontinued
-
-
-
-
-
-
-
1,355.8
-
operations
Consolidated profit (loss) for the period
120.2
(140.7)
(0.1)
(16.2)
(47.3)
82.4
(1.7)
1,813.0
-
Attributable to the group
120.2
(78.8)
(0.2)
(16.3)
(39.2)
69.4
55.1
1,726.5
-
Attributable to non-controlling interests
-
(61.9)
0.1
0.1
(8.1)
13.0
(56.8)
86.6
-
September 30,
September 30,
Profit (loss) per share (€)
2024
2023
Basic - continuing operations
0.41
2.84
€m September 30,
2023

Financial calendar and other regulated information

Strategic Update November 7, 2024
Annual results 2024 March 13, 2025
Results as of March 31, 2025 May 2, 2025
Ordinary General Meeting 2025 May 2, 2025
Dividend payment May 13, 2025
Report on payments to governments available on GBL's website May 30, 2025
Half-year results 2025 July 31, 2025

These dates may be subject to change.

Quiet periods

February 11 – March 13, 2025 April 17 – May 2, 2025 July 1 – July 31, 2025

For more information

Xavier Likin Chief Financial Officer Tel: + 32 2 289 17 72 [email protected]

Alison Donohoe Head of Investor Relations Tel : +32 2 289 17 64 [email protected]

About Groupe Bruxelles Lambert

Groupe Bruxelles Lambert ("GBL") is an established investment holding company, with seventy years of stock exchange listing and a net asset value of €16.3bn at the end of September 2024. As a leading and active investor in Europe, GBL focuses on long-term value creation with the support of a stable family shareholder base. As a responsible company and investor, GBL perceives ESG factors as being inextricably linked to value creation.

GBL aims to grow its diversified high-quality portfolio of listed, private and alternative investments.

GBL is focused on delivering meaningful growth by providing attractive returns to its shareholders through a combination of growth in its net asset value per share, a sustainable dividend and share buybacks.

GBL is listed on Euronext Brussels (Ticker: GBLB BB; ISIN code: BE0003797140) and is included in the BEL20 index.

Talk to a Data Expert

Have a question? We'll get back to you promptly.